X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 11c

Go back to X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 11c

X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 5, 2020 8:00 AM EST

WHIM Phase 2 data published in Blood - the Official Journal of the American Society of Hematology

Granted Fast Track Designation by FDA for mavorixafor in WHIM syndrome

Key leadership appointments including CSO and Board Director

Conference call today at 8:30 a.m. ET

BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) --... More